News and events
When results are so encouraging, the path is traced: one step at a time towards the cure ~ Hemera’s Team
Hemera receives the Seal of Excellence from the European Commission for the REMaST project
Hemera recently participated in the prestigious European program EIC Accelerator, promoted by the European Commission to support high-impact...
European Patent Granted for REMaST: a Key Step in Enhancing Hemera’s Intellectual Property
The European patent for REMaST, Hemera’s proprietary technology for nervous tissue regeneration, has been published in Issue 24/25 of the European Patent Office (EPO) Bulletin on June 11, 2025…
We warmly welcome Statuto Fiduciaria among Hemera’s supporters
We are pleased to announce the entry of Statuto Fiduciaria as a new shareholder, representing the subscribers of the SAFE
Hemera goes to Brussels for the Final Phase of the EIC Accelerator
Hemera is among the 7 Italian startups out of 71 selected across Europe, that successfully passed the second phase of the EIC Accelerator selection process
Hemera at the Chamber of Deputies to Receive the 2025 America Innovation Award
Hemera has been selected among 300 Italian entrepreneurial ventures as a recipient of the America Innovation Award, promoted by the Italy–USA Foundation and presented at the Chamber of Deputies in Rome
Research by Hemera Scientists on Nature Immunology Review
The study titled “Tumor-associated macrophages enhance tumor innervation and spinal cord repair”, to which our researchers contributed, was recently published by Nature Reviews Immunology
Interview with Hemera on Byoblu: Focus on Cell Therapies for Nerve Regeneration
Byoblu interviews Professors Bifari and Locati, co-founders of Hemera, to explore the scientific foundations of our REMaST cell therapy
Hemera Receives a “GO” in Phase 1 of the EIC Accelerator
We are pleased to announce that our proposal successfully passed the short application stage, receiving the first “GO” in the evaluation process.
Cytotherapy Mentions Hemera as One of the Most Promising Players in Cell Therapy
Hemera was recently featured in Cytotherapy, the official journal of the International Society for Cell & Gene Therapy,
Preprint Published: Hemera’s REMaST Research Marks a Breakthrough in Nerve Regeneration
We are pleased to announce the preprint publication of the scientific article presenting the results of our groundbreaking research on the REMaST therapy
Hemera Among the Top 8 Health Startups
We are proud to announce that Hemera has been included in the list of the 8 emerging startups revolutionizing the healthcare sector, as reported by Milano Finanza.
Hemera Wins the 2024 Italian Master Startup Award in the Life Sciences MED-Tech Category
Hemera has been named co-winner of the 2024 IMSA – Italian Master Startup Award in the Life Sciences MED-Tech category, alongside ALBA Robot.
Hemera Named Finalist at the 2024 Italian Master Startup Award
We are pleased to announce that Hemera Pharma has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research.
Hemera Presents the Progress of REMaST®️ Therapy at the FENS Forum 2024
Hemera Pharma is participating in the FENS Forum 2024, the leading European congress on neuroscience, held from June 25 to 29 in Vienna. The teams from the Therapy Development Department and the Research and Development Department, led by Prof. Ilaria Decimo, will present the development of the REMaST®️ therapy (Regenerative Educated Macrophages Self Transplantation).
We are pleased to welcome Humanitas Mirasole S.p.A. among Hemera’s shareholders
We are pleased to announce that Istituto Clinico Humanitas Mirasole S.p.A. has joined Hemera’s shareholding structure
Hemera at ISCT 2024: Innovation and Cutting-Edge Cell Therapies
Hemera enthusiastically participated in ISCT 2024, the event organized by the International Society for Cell & Gene Therapy, held in Vancouver...
Innovation Coffee: Advancements in REMaST® Therapy and the Mission to Regenerate Nervous Tissue.
In the context of the "Healing the Incurable" Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the...
Scientific Venture Capital Selects Hemera Among Italy’s Most Innovative Deep-Tech Companies
Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative...
Scientifica Venture Capital selects Hemera among the most innovative deep-tech companies in Italy
Important Recognition for REMaST® Therapy: A New Perspective for Patients with Spinal Cord Injuries Hemera has been selected among the most...
A study has been initiated to observe patients with traumatic and complete spinal cord injury.
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective...
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy
The prospective observational clinical study is now underway, involving patients with acute, complete traumatic spinal cord injury, who will be monitored over a 12-month period during their neurorehabilitation journey.
Hemera Pharma: Excellence and Innovation Recognized with Women Startup Award in Regenerative Medicine
Hemera Pharma Receives Women Startup Award for Excellence in Regenerative Medicine We are delighted to share Hemera Pharma's recent achievements in...
Cristiana Vignoli, CEO of Hemera, among the Top 7 Innovative Entrepreneurs at the GammaDonna Award 2023.
Our CEO, Cristiana Vignoli, has been selected for the #FAB50 shortlist of the 2023 GammaDonna Award and is among the 7 finalists nominated for the Prize.
2nd Quarter 2023
Hemera Pharma among the 50 most innovative companies of the 2023 “Premio Gamma Donna”
Hemera is among the 50 stories of companies with a high rate of innovation led by women who interpret the objective of the Premio Gamma Donna
Hemera receives Orphan Drug Designation for REMaST® therapy
REMaST® obtains from the European Commission the designation of orphan drug for acute spinal injuries
Hemera Receives Orphan Drug Designation for REMaST® Therapy
The advanced cell therapy REMaST®, developed by Hemera, has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries
Changed the structure of the Board of Directors
Hemera extend thanks to Aldo Cocchiglia for his contribution to the company’s advancement and success
New Composition of the Board of Directors
For personal reasons, Aldo Cocchiglia will step down from the Board of Directors effective May 3, 2023.
Hemera achieves an important milestone with the granting of the patent
The positive evaluation by the Italian Patent and Trademark Office has led to the long-awaited recognition of REMaST® therapy
Stay informed on Hemera’s latest activities with our Newsletter.